Spots Global Cancer Trial Database for advanced
Every month we try and update this database with for advanced cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | NCT02989064 | Urothelial Carc... Head and Neck C... Melanoma Bladder Urothel... | Autologous gene... | 18 Years - 75 Years | Adaptimmune | |
| Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma | NCT03359018 | Progression-fre... Overall Surviva... Clinical Benefi... Toxicity | Apatinib SHR-1210 | 11 Years - | Peking University People's Hospital | |
| Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy | NCT01869218 | Hematologic Neo... | 18 Years - | University of Colorado, Denver | ||
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | NCT01562028 | Lung Cancer | Erlotinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates | NCT00104650 | Bone Metastases... Bone Metastases... Bone Metastases... | AMG 162 180 mg ... IV Bisphosphona... AMG 162- 180 mg... | 18 Years - | Amgen | |
| EDMONd - Elemental Diet in Bowel Obstruction | NCT03150992 | Ovarian Cancer Ovarian Neoplas... Ovarian Disease Peritoneal Neop... Peritoneal Dise... Metastatic Ovar... Primary Periton... Abdominal Neopl... Bowel Obstructi... | Elemental 028 E... | 18 Years - 90 Years | Royal Surrey County Hospital NHS Foundation Trust | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors | NCT05180799 | Solid Tumor, Ad... NSCLC Urothelial Carc... Gastric Cancer Small Cell Lung... Hepatocellular ... Cervical Carcin... Melanoma Renal Cell Carc... Carcinoma | BA3071 Nivolumab Pembrolizumab | 18 Years - | BioAtla, Inc. | |
| Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | NCT01230697 | Kidney Cancer Liver Cancer | Sorafenib | 18 Years - | University of Turin, Italy | |
| Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | NCT01879085 | Sarcoma | Docetaxel Gemcitabine Vorinostat Pegfilgrastim | 18 Years - | University of Pittsburgh | |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients | NCT03224208 | Melanoma Melanoma (Skin) Melanoma Stage | Vemurafenib Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer | NCT01492543 | Breast Cancer | Tegafur Gimerac... | 18 Years - 75 Years | ChineseAMS | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | NCT00661830 | Adenocarcinoma | Gemcitabine Placebo Sorafenib | 18 Years - | Johannes Gutenberg University Mainz | |
| Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | NCT02711007 | Osteosarcoma Metastasis | apatinib | 16 Years - | Peking University People's Hospital | |
| Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00356122 | Non-Small Cell ... | Docetaxel Oxaliplatin Bevacizumab | 18 Years - | Sanofi | |
| Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor | NCT01845675 | Advanced Well-d... | temozolomide or... | 18 Years - | Peking Union Medical College Hospital | |
| Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | NCT03167619 | Triple Negative... | Olaparib Oral P... Olaparib Oral P... | 21 Years - | Duke University | |
| Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer | NCT01492543 | Breast Cancer | Tegafur Gimerac... | 18 Years - 75 Years | ChineseAMS | |
| Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | NCT03013101 | Advanced Melano... Metastatic Mela... | humanized anti-... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study | NCT04258137 | Colorectal Canc... Non Small Cell ... | Liquid biopsy | 18 Years - | Institut Bergonié | |
| VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer | NCT00431704 | Metastatic Brea... | vinorelbine carboplatin trastuzumab | 18 Years - 75 Years | National Cancer Institute, Naples | |
| END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | NCT00401635 | Endometrial Can... | liposomal doxor... carboplatin | 18 Years - 75 Years | National Cancer Institute, Naples | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis | |
| Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | NCT01943422 | Melanoma | High-dose Inter... Vemurafenib | 18 Years - | University of Pittsburgh | |
| Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma | NCT02438501 | Recurrent Folli... | Low-dose involv... Involved-field ... | 18 Years - 65 Years | Wuhan University | |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | NCT00548093 | Carcinoma, Non ... | PF-00299804 PF-00299804 | 18 Years - 99 Years | Pfizer | |
| FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | NCT01747551 | Esophageal Canc... Gastric Cancer | Oxaliplatin Leucovorin Fluorouracil Ziv-aflibercept | 18 Years - | Dana-Farber Cancer Institute | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | NCT05755113 | Soft Tissue Sar... | Tigilanol Tigla... | 18 Years - | QBiotics Group Limited | |
| Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer | NCT00394147 | Head and Neck C... | pemetrexed gemcitabine | 18 Years - | Fox Chase Cancer Center | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | NCT00437749 | Non-Small Cell ... | CBT-1 Placebo | 18 Years - | CBA Research | |
| Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | NCT00356122 | Non-Small Cell ... | Docetaxel Oxaliplatin Bevacizumab | 18 Years - | Sanofi | |
| Metronomic Chemotherapy in Advanced Gastric Cancer | NCT02855788 | Metastatic Gast... Locally Advance... | Paclitaxel 60mg... | 18 Years - 70 Years | Huashan Hospital | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | NCT00609804 | Non-Small Cell ... | Sorafenib Erlotinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | NCT00769067 | Non-small Cell ... | Erlotinib PF-00299804 | 18 Years - 99 Years | Pfizer | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma | NCT04824352 | Effect of Drug Toxicity, Drug | apatinib | 12 Years - 70 Years | Peking University People's Hospital | |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | NCT01719744 | Advanced Metastatic Soft Tissue Sar... | ENMD-2076 | 18 Years - | University Health Network, Toronto | |
| Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | NCT01907607 | Advanced Gastro... | PD 0332991 | 18 Years - | Institut Bergonié | |
| Various G-CSF Regimens to Prevent Infection During Chemotherapy | NCT00536081 | Breast Cancer Chemotherapy Febrile Neutrop... | pegfilgrastim | 18 Years - | Academisch Ziekenhuis Maastricht | |
| A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients | NCT00201825 | Lung Cancer Non-Small-Cell ... | Capecitabine Docetaxel | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Axitinib in Advanced Carcinoid Tumors | NCT01435122 | Carcinoid Tumor | Axitinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335 | Soft Tissue Sar... Advanced Cancer | Apatinib | 16 Years - | Peking University People's Hospital | |
| A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients | NCT01100801 | Recurrent Gastr... | TS-1 with cispl... TS-1 with oxali... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer | NCT01937689 | Breast Cancer | Pyrotinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | NCT03013101 | Advanced Melano... Metastatic Mela... | humanized anti-... | 18 Years - | Shanghai Junshi Bioscience Co., Ltd. | |
| Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | NCT01524783 | Advanced NET of... Advanced NET of... Neuroendocrine ... | Everolimus Placebo Best suportive ... | 18 Years - | Novartis | |
| Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | NCT00609804 | Non-Small Cell ... | Sorafenib Erlotinib | 18 Years - | SCRI Development Innovations, LLC | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer | NCT00881296 | Non-Small Cell ... | gemcitabine and... Gemcitabine | 76 Years - | Hamamatsu University | |
| Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors | NCT01096030 | Neoplasms | Regorafenib (St... | 18 Years - | Bayer | |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | NCT01719744 | Advanced Metastatic Soft Tissue Sar... | ENMD-2076 | 18 Years - | University Health Network, Toronto | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | NCT02405910 | Non-small Cell ... | Nab-paclitaxel Gemcitabine | 18 Years - | West Virginia University | |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335 | Soft Tissue Sar... Advanced Cancer | Apatinib | 16 Years - | Peking University People's Hospital | |
| Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | NCT02466568 | Lung Cancer Adenocarcinoma ... | Nivolumab GM.CD40L Vaccin... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer | NCT00291577 | Breast Neoplasm... | Sunitinib (Sute... Taxotere | 18 Years - | Pfizer | |
| MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial | NCT03287427 | Colorectal Canc... Adenoid Cystic ... | TetMYB Vaccine BGB-A317 | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | NCT00705549 | Non-Small-Cell ... | Gemcitabine Cisplatin Docetaxel Cisplatin Vinorelbine Pemetrexate | 18 Years - | Hellenic Oncology Research Group | |
| Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors | NCT01544322 | Solid Tumors | ME-344 | 18 Years - | MEI Pharma, Inc. | |
| Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer | NCT00049998 | Non-Small-Cell ... | topotecan | 18 Years - | GlaxoSmithKline | |
| A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors | NCT01731925 | Carcinoid Tumor... | Lanreotide Placebo (for su... Sunitinib | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | NCT04832438 | Salivary Gland ... Adenoid Cystic ... Salivary Gland ... Salivary Gland ... | 9-ING-41 Carboplatin | 18 Years - | Actuate Therapeutics Inc. | |
| Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients | NCT01336062 | Gastric Adenoca... | Nanoparticle Al... | 18 Years - 75 Years | Peking University | |
| Role of Surgery in Advanced Ovarian Cancer | NCT03980028 | Ovarian Cancer | 18 Years - | Institut Claudius Regaud | ||
| Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours | NCT06345079 | Neuroendocrine ... | Cessation of so... Continuation of... | 18 Years - | Australasian Gastro-Intestinal Trials Group | |
| Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates | NCT00104650 | Bone Metastases... Bone Metastases... Bone Metastases... | AMG 162 180 mg ... IV Bisphosphona... AMG 162- 180 mg... | 18 Years - | Amgen | |
| Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer | NCT00841113 | Prostate Cancer | Abarelix Goserelin plus ... | 18 Years - | Speciality European Pharma Limited | |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | NCT02646748 | Colorectal Canc... Endometrial Can... Melanoma Head and Neck C... Lung Cancer MMR-deficient T... Breast Cancer Pancreatic Canc... Renal Cell Carc... Solid Tumors UC (Urothelial ... | Pembrolizumab itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer | NCT00683358 | Pancreatic Canc... Pancreas Neopla... | VEGFR1-A24-1084... | 20 Years - 85 Years | Tokyo University | |
| GVAX in Advanced Prostate Cancer Patients Made Lymphopenic | NCT00122005 | Prostate Cancer | GM-CSF gene tra... | 18 Years - | Providence Health & Services | |
| PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | NCT03685591 | Breast Neoplasm... Prostate Neopla... Neoplasms, Squa... Melanoma Mesothelioma Pancreatic Neop... Colorectal Neop... Carcinoma, Rena... Liver Neoplasms | PF-06952229 Enzalutamide | 18 Years - | Pfizer | |
| A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | NCT00465725 | Bladder Cancer Breast Cancer Colorectal Canc... Gastrointestina... Head and Neck C... Lung Cancer Ovarian Cancer Pancreatic Canc... Prostate Cancer | Picoplatin | 18 Years - | Poniard Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
